We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients
from a well-defined area during month 1–13 of the pandemic. Sixty patients (median age 71 …

Standard treatment options in classic HCL (cHCL) result in high response rates and near
normal life expectancy. However, the disease itself and the recommended standard …

In this retrospective international multicenter study, we describe the clinical characteristics
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …

INTRODUCTION: The COVID-19 pandemic is an unprecedented global crisis profoundly
affecting oncology care delivery. PURPOSE: This study will describe the occupational and …

Background There is scarcity of data on outcome of COVID-19 in patients with hematological
malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality …

Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients have increased
morbidity and mortality rates of COVID‐19 due to immunosuppression associated with the …

Vaccination against SARS-CoV-2 is considered as the most important preventive strategy
against COVID-19, but its efficacy in patients with hematological malignancies is largely …

Novel coronavirus disease 2019 (COVID-19) severity is highly variable, with pediatric
patients typically experiencing less severe infection than adults and especially the elderly …

Importance There are limited comparative data on the durability of neutralizing antibody
(nAb) responses elicited by messenger RNA (mRNA) vaccines against the SARS-CoV-2 …

Introduction Patients with cancer are more vulnerable to COVID-19 than the general
population. Accordingly, it is necessary to identify the risk factors for death in patients with …